GLUE Monte Rosa Therapeutics Inc
Price (delayed)
$4.41
Market cap
$271.26M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.98
Enterprise value
$84.86M
Highlights
Monte Rosa Therapeutics's EPS has soared by 63% YoY and by 46% from the previous quarter
The net income has grown by 46% YoY and by 39% from the previous quarter
The quick ratio has dropped by 60% since the previous quarter and by 53% year-on-year
Key stats
What are the main financial stats of GLUE
Market
Valuations
Earnings
Shares outstanding
61.51M
Market cap
$271.26M
Enterprise value
$84.86M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.22
Price to sales (P/S)
4.31
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.12
Revenue
$75.62M
Gross profit
$75.62M
Operating income
-$81.11M
Net income
-$72.7M
EBIT
-$70.13M
EBITDA
-$62.01M
Free cash flow
$38.01M
Per share
Balance sheet
Liquidity
EPS
-$0.98
EPS diluted
-$0.98
Free cash flow per share
$0.51
Book value per share
$3.63
Revenue per share
$1.02
TBVPS
$5.94
Total assets
$438.73M
Total liabilities
$215.8M
Debt
$42.72M
Equity
$222.94M
Working capital
$220.49M
Debt to equity
0.19
Current ratio
2.4
Quick ratio
2.4
Net debt/EBITDA
3.01
Margins
Efficiency
Dividend
EBITDA margin
-82%
Gross margin
100%
Net margin
-96.1%
Operating margin
-107.3%
Return on assets
-21.3%
Return on equity
-36.1%
Return on invested capital
-41.2%
Return on capital employed
-24.9%
Return on sales
-92.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
GLUE stock price
How has the Monte Rosa Therapeutics stock price performed over time
Intraday
-0.45%
1 week
-19.67%
1 month
-19.82%
1 year
-35.15%
YTD
-36.46%
QTD
-4.96%
Financial performance
How have Monte Rosa Therapeutics's revenue and profit performed over time
Revenue
$75.62M
Gross profit
$75.62M
Operating income
-$81.11M
Net income
-$72.7M
Gross margin
100%
Net margin
-96.1%
The operating margin has surged by 88% since the previous quarter
The net margin has surged by 88% since the previous quarter
The net income has grown by 46% YoY and by 39% from the previous quarter
The operating income has increased by 43% year-on-year and by 37% since the previous quarter
Growth
What is Monte Rosa Therapeutics's growth rate over time
Valuation
What is Monte Rosa Therapeutics stock price valuation
P/E
N/A
P/B
1.22
P/S
4.31
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.12
Monte Rosa Therapeutics's EPS has soared by 63% YoY and by 46% from the previous quarter
GLUE's P/B is 28% below its last 4 quarters average of 1.7
The equity rose by 24% year-on-year and by 9% since the previous quarter
GLUE's price to sales (P/S) is 96% less than its last 4 quarters average of 120.2
Efficiency
How efficient is Monte Rosa Therapeutics business performance
Monte Rosa Therapeutics's ROS has soared by 88% from the previous quarter
Monte Rosa Therapeutics's ROA has soared by 55% YoY and by 45% from the previous quarter
GLUE's ROE is up by 45% year-on-year and by 42% since the previous quarter
The ROIC has grown by 35% from the previous quarter and by 29% YoY
Dividends
What is GLUE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for GLUE.
Financial health
How did Monte Rosa Therapeutics financials performed over time
GLUE's total assets is 103% greater than its total liabilities
The total liabilities has surged by 97% since the previous quarter and by 73% year-on-year
The company's current ratio has shrunk by 60% QoQ and by 53% YoY
The debt is 81% smaller than the equity
The debt to equity has contracted by 27% YoY and by 10% from the previous quarter
The equity rose by 24% year-on-year and by 9% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.